文献速递肾癌与肾肿瘤

美国食品药品监督管理局汇总分析:转移性肾细胞癌一线联合治疗按风险分组的生存获益

A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma.
PubMed 文献 · Eur Urol · 2023-06-02

该汇总分析纳入2019至2021年获批的四项IO/TKI一线治疗转移性肾细胞癌试验,共3098例患者(839例 favorable-risk)。按IMDC风险分组分析显示,IO/TKI在intermediate/poor-risk组有OS获益(HR 0.64),但在favorable-risk组尚未显示OS获益(HR 1.24);两组的PFS均有获益。

要点

  • IO/TKI一线治疗在intermediate/poor-risk组显示OS获益(HR 0.64;95%CI 0.55,0.75)。
  • Favorable-risk组尚未显示OS获益(HR 1.24;95%CI 0.86,1.78)。
  • Favorable-risk组与intermediate/poor-risk组的PFS均有获益。

核心结论

  • IO/TKI一线联合治疗的获益在intermediate/poor-risk组大于favorable-risk组;favorable-risk患者的OS获益尚未得到证实,需要更长随访。

研究设计与样本

  • 汇总分析四项一线mRCC的IO/TKI联合治疗试验,纳入3098例患者(839例favorable-risk),获批时间为2019至2021年。
  • 所有试验均以IO/TKI联合方案为治疗组、舒尼替尼为对照组。
  • 按IMDC风险分组分析PFS和OS,并将favorable-risk以外的患者合并为intermediate/poor-risk组。

主要发现

  • 在调整基线协变量的探索性分析中,favorable-risk组IO/TKI尚未显示OS获益(HR 1.24;95%CI 0.86,1.78),而intermediate/poor-risk组显示OS获益(HR 0.64;95%CI 0.55,0.75)。
  • IO/TKI在favorable-risk组(HR 0.63;95%CI 0.50,0.79)和intermediate/poor-risk组(HR 0.52;95%CI 0.45,0.60)均显示PFS获益。
  • 客观缓解率方面,联合组与舒尼替尼组在favorable-risk组的差异(68.2% vs 49.9%)小于intermediate/poor-risk组(59.9% vs 36.5%)。
  • 完全缓解率方面,favorable-risk组的差异(15.3% vs 6.0%)大于intermediate/poor-risk组(9.1% vs 3.4%)。

局限性

  • 本文为探索性分析。
  • favorable-risk患者的OS数据尚不成熟,需要更长随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While frontline immuno-oncology/tyrosine kinase inhibitor (IO/TKI) combination therapy has established a benefit in metastatic renal cell carcinoma (mRCC), this may differ by International Metastatic RCC Database Consortium (IMDC) risk grouping. Looking at individual trials, we noted an apparently smaller magnitude of benefit for favorable-risk disease. OBJECTIVE: We aimed to assess treatment benefit by risk groupings, especially in favorable-risk, augmenting patient numbers via a pooled analysis. DESIGN, SETTING, AND PARTICIPANTS: We pooled four frontline mRCC trials of IO/TKI combinations including 3,098 patients (839 favorable-risk) with approvals from 2019 to 2021. INTERVENTION: All trials used IO/TKI combinations as the treatment option and sunitinib as the control. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We analyzed progression-free survival (PFS) and overall survival (OS) by IMDC groupings. To specifically address the favorable-risk group, we combined all others into an intermediate/poor-risk group. RESULTS AND LIMITATIONS: In this exploratory analysis adjusted for baseline covariates, IO/TKI combinations have yet to demonstrate an OS benefit in favorable-risk (hazard ratio [HR] 1.24; 95% confidence interval [CI]: 0.86, 1.78) despite demonstrating an OS benefit in the intermediate/poor-risk group (HR 0.64; 95% CI: 0.55, 0.75). In contrast, IO/TKI demonstrated a PFS benefit for both the favorable-risk (HR 0.63; 95% CI: 0.50, 0.79) and the intermediate/poor-risk (HR 0.52; 95% CI: 0.45, 0.60) group. For objective response rate, a smaller difference was observed between the combination and sunitinib arms in favorable-risk (68.2% vs 49.9%) versus intermediate/poor-risk (59.9% vs 36.5%) groups, while the difference in complete response rate was larger for favorable-risk (15.3% vs 6.0%) versus intermediate/poor-risk (9.1% vs 3.4%) groups. CONCLUSIONS: The frontline IO/TKI combination therapy benefit was shown to be greater in the intermediate/poor-risk group than in the favorable-risk group. The OS benefit observed with IO/TKI for mRCC has yet to be demonstrated for favorable-risk patients; longer follow-up is needed. PATIENT SUMMARY: Patients with intermediate/poor-risk metastatic renal cell carcinoma derive an overall survival benefit from immuno-oncology/tyrosine kinase inhibitor combinations, while data for favorable-risk remain immature.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Lee D, Gittleman H, Weinstock C, et al. A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma. Eur Urol. 2023. PMID: 37271635. doi:10.1016/j.eururo.2023.05.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。